EUCTR2017-000737-31-GB进行中（未招募）1 期
A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of octreotide capsules in patients who previously tolerated and demonstrated biochemical control on injectable somatostatin receptor ligands (SRL) treatment - OPTIMA
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Adult subjects, aged =18 years old at the first Screening visit.
- •2. Patients with active acromegaly, defined as documented evidence of GH-secreting pituitary tumor based on MRI/Pathology report and documented evidence of IGF-1 levels =1.3 × ULN. This needs to be at least 3 months following pituitary surgery in
- •those patients who had prior pituitary surgery.
- •3. Received parenteral SRL monotherapy (octreotide or lanreotide but not pasireotide) for at least 6 months with a stable dose for at least the last three months of therapy.
- •4. Average IGF-1 of 2 assessments obtained during the Screening period is =1 * ULN.
- •5. Patients able and willing to comply with the requirements of the protocol at the time of Screening.
- •6. Women who are of childbearing potential should use an acceptable method for birth control. Acceptable methods include hormonal contraception (oral contraceptives – as long as on stable dose, patch, implant, and injection), intrauterine devices, or double
- •barrier methods (e.g. vaginal diaphragm/ vaginal sponge plus condom, or condom plus spermicidal jelly), sexual abstinence or a vasectomized partner. Women may be surgically sterile or at least 1-year post-last menstrual period. Women taking oral contraception containing levonorgestrel should either change treatment (at least one month prior to first study medication dose) or use a mechanical barrier method.
- •7. Patients able to understand and sign written informed consent to participate in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1. Patients taking injections of long-acting SRLs off label (unlabeled doses or dosing interval. e.g. 60 or 90 mg lanreotide every 8 weeks or 30 mg octreotide every 6 or 8 weeks).
- •2. Patients who previously participated in CH-ACM-01 or OOC-ACM-302 (MPOWERED).
- •3. Symptomatic cholelithiasis.
- •4. Conventional or stereotactic Radiotherapy any time in the past.
- •5. Undergone pituitary surgery within six months prior to screening or have elective pituitary surgery (or other elective surgery that may affect compliance with protocol or confound study outcomes), planned within the course of the core study.
- •6. High-risk pattern of pituitary tumor location on pituitary magnetic resonance imaging (MRI)/Computed tomography (CT) as per medical history or most recent MRI/CT.
- •7. History of unstable angina or acute myocardial infarction within the 12 weeks preceding the screening visit or other clinically significant cardiac disease at the time of screening as judged by the Principal Investigator.
- •8. Any clinically significant uncontrolled nervous system, gastrointestinal (GI), renal, pulmonary, or hepatic concomitant disease that in the Investigator’s opinion would preclude patient participation.
- •9. Evidence of active malignant disease or malignancies diagnosed within the previous one year (except for basal cell carcinoma and uncomplicated – up to stage 1 squamous cell carcinoma that has been excised and cured).
- •10. Known allergy or hypersensitivity to any of the test compounds or materials.
- •11. Known uncontrolled diabetes defined as having a fasting glucose > 150 mg/dL (8.3 mmol/L) or glycosylated hemoglobin (HbA1c) = 8% (patients can be rescreened after diabetes is brought under adequate control, or in case HbA1c < 8%).
- •12. Known defects in visual fields due to optic chiasmal compression or other neurological signs, related to the pituitary tumor mass. Patients with long-standing (>12 months), fixed, minor defects may be considered on a case-by-case basis after consultation with the
- •medical monitor.
- •13. Female patients who are pregnant or lactating or intending to become pregnant during the study.
- •14. Known history of immunodeficiency (e.g., HIV positive).
- •15. ALT, AST or ALP > 3 * ULN or Total Bilirubin >1.5 * ULN.
- •16. Undergone major surgery/surgical therapy for any cause within four weeks prior to enrollment or planned procedure during the study.
- •17. Known hypothyroidism or hypocortisolism not adequately treated with a stable dose of thyroid or steroid hormone replacement therapy for = 12 weeks.
- •18. Any condition that may jeopardize study participation (e.g., clinically significant abnormal screening clinical or laboratory finding during screening), the interpretation of study results or may impede the ability to obtain informed consent (e.g., mental condition).
- •19. History of illicit drug or alcohol abuse within five years.
- •20. Intake of an investigational drug within 30 days prior to initiation of study treatment.
- •21. Treatment with pegvisomant within 24 weeks before the first screening visit.
- •22. Treatment with dopamine agonists within 12 weeks before the screening visit.
- •23. Treatment with pasireotide within 24 weeks before the first screening visit.
研究者
相似试验
进行中（未招募）
不适用
Study of Epratuzumab versus Placebo in subjects with moderate to severe general Systemic Lupus Erythematosus (SLE)Systemic Lupus ErythmatosusMedDRA version: 14.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-018563-41-CZCB Inc.780
尚未招募
3 期
Study of Epratuzumab vs Placebo in subjects with moderate to severe general Systemic Lupus ErythematosusCTRI/2011/11/002114CB Inc1,053
进行中（未招募）
1 期
Study of Epratuzumab versus Placebo in subjects with moderate to severe general Systemic Lupus Erythematosus (SLE)EUCTR2010-018563-41-GBCB Inc.793
进行中（未招募）
1 期
Study of Epratuzumab versus Placebo in subjects with moderate to severe general Systemic Lupus Erythematosus (SLE)Systemic Lupus ErythmatosusMedDRA version: 16.0 Level: PT Classification code 10042945 Term: Systemic lupus erythematosus System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-018565-26-GBCB Inc.791
已完成
3 期
Study of Epratuzumab versus Placebo in subjects with moderate to severe general Systemic Lupus Erythematosus (SLE)CTRI/2011/11/002115CB Inc1,053